Viral Vector Gene Expression Balance for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches struggle to effectively stimulate an immune response against cancer and viral infections due to barriers such as immune evasion strategies employed by cancer cells and viruses.
Innovation Solution
A novel vector system comprising nucleic acid sequences encoding 4-1BB ligand (4-1BBL), single chain IL-12 (scIL-12), and IL-2, with a specific organizational structure that enhances the expression of 4-1BBL relative to scIL-12 and IL-2, is used to convert an inactive into an active immune microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy vectors are used to deliver immune therapy, then cancer cells can be targeted for destruction, but the immune response is insufficient due to immune evasion strategies by cancer cells and viruses
Solution Approach 1:
The patent combines multiple immune-stimulating genes (4-1BBL, scIL-12, and IL-2) into a single viral vector system. This merging of multiple therapeutic functions into one vector enables simultaneous delivery of costimulatory signals and cytokines, creating a synergistic immune response that overcomes cancer cell immune evasion strategies more effectively than single-gene vectors.
Solution Approach 2:
The viral vector system functions as a composite biological material that integrates multiple gene products (4-1BBL protein, scIL-12 protein, and IL-2 protein) within a single delivery platform. This composite approach allows the vector to present multiple immune-stimulating activities concurrently, enhancing the overall immunotherapy effectiveness against cancer and viral infections.
2Power
If viral vectors are used to deliver immune activating modalities, then tumor-specific immunity can be enhanced, but the expression levels of immune components may be insufficient or unbalanced
Solution Approach 1:
The patent employs different promoter strengths for different genes within the same vector system. The 4-1BBL gene is driven by a strong promoter to ensure high expression levels, while IL-2 and scIL-12 are driven by weaker promoters. This local differentiation of promoter strength creates an optimized expression profile where each component is produced at its biologically optimal level, maximizing immune activation capacity.
Solution Approach 2:
The patent systematically varies the promoter strength parameter across different gene expressions within the vector. By adjusting the promoter strength from strong (for 4-1BBL) to weak (for IL-2 and scIL-12), the system achieves an optimal balance in protein expression levels that enhances immune response effectiveness without producing excessive amounts of any single component.
Data Source
AI summary
Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5′ to 3′ orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.